Related Experiment Videos
Ranitidine: a new H2-receptor antagonist.
Clinical Pharmacy
|November 1, 1982
Summary
Ranitidine, a new H2-receptor antagonist, effectively treats ulcers and related conditions with fewer side effects than cimetidine. Its favorable safety profile makes it a preferred choice in many clinical scenarios.
Area of Science:
- Pharmacology
- Gastroenterology
Background:
- Ranitidine is a novel H2-receptor antagonist.
- It inhibits gastric acid secretion.
- Its chemical structure differs from cimetidine.
Purpose of the Study:
- Review ranitidine's pharmacology, pharmacokinetics, clinical efficacy, adverse reactions, drug interactions, and dosage.
- Compare ranitidine with cimetidine.
Main Methods:
- Review of pharmacology and pharmacokinetics.
- Analysis of controlled clinical trials.
- Comparison with cimetidine based on efficacy and safety data.
Main Results:
- Ranitidine is a potent gastric acid secretion inhibitor.
- It is effective for duodenal/gastric ulcers, Zollinger-Ellison syndrome, and aspiration prophylaxis.
- Ranitidine shows a low incidence of adverse effects and fewer drug interactions compared to cimetidine.
Conclusions:
- Ranitidine is similar to cimetidine in efficacy.
- Ranitidine possesses a superior adverse-effects profile.
- Ranitidine is likely to be the preferred H2-receptor antagonist in specific clinical situations.